Evidence map›Paper›PMID 40487589›Full record

ArticleNeuro-oncology practice2025

Children with medulloblastoma treated with modified ACNS0821 temozolomide, irinotecan, and bevacizumab: The Seattle Children's Hospital experience.

Rebecca Ronsley, Miranda C Bradford, Erin E Crotty, Nicholas A Vitanza, Daniel V Runco, Jeffrey Stevens, Corinne Hoeppner, Susan L Holtzclaw, Amy R Wein, Amy Lee and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Bevacizumab in Pediatric Neuro-Oncology.Current oncology (Toronto, Ont.) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rebecca RonsleyFred Hutch Cancer Center, Seattle, Washington, USA.
Miranda C BradfordBiostatistics Epidemiology and Analytics in Research (BEAR) Core, Seattle Children's Research Institute, Seattle, Washington, USA.
Erin E CrottyFred Hutch Cancer Center, Seattle, Washington, USA.
Nicholas A VitanzaFred Hutch Cancer Center, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-3966-4985
Daniel V RuncoFred Hutch Cancer Center, Seattle, Washington, USA.
Jeffrey StevensDepartment of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, Washington, USA.
Corinne HoeppnerDepartment of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, Washington, USA.
Susan L HoltzclawDepartment of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, Washington, USA.
Amy R WeinDepartment of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, Washington, USA.
Amy LeeDivision of Neurosurgery, Seattle Children's Hospital and Department of Neurological Surgery, University of Washington, Seattle, Washington, USA.
Bonnie L ColeDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Ralph ErmoianDepartment of Radiation Oncology, University of Washington, Seattle, Washington, USA.
Sarah E S LearyFred Hutch Cancer Center, Seattle, Washington, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Effective therapy for medulloblastoma at the time of relapse is limited. The objective of this study is to review outcomes from the Seattle Children's Hospital (SCH) institutional standard therapy for relapsed medulloblastoma, modified from the published ACNS0821 regimen. Methods: Retrospective review of patients treated for relapsed medulloblastoma from 2012-2024 treated with modified ACNS0821 therapy, including combination bevacizumab, irinotecan, and temozolomide, referred to as " Results: Fifteen patients were treated with TIB for relapsed medulloblastoma at SCH (median age 5.81 (0.21-23.6) years, 60% male). Twelve patients completed planned therapy. Therapy was discontinued for toxicity ( Conclusions: TIB was well-tolerated in pediatric patients with relapsed medulloblastoma, and outcomes were similar to those published in clinical trials. TIB therapy should be considered for patients with relapsed medulloblastoma, especially patients with limited access to care due to travel barriers.

Indexed as

childrenmedulloblastomapediatricrelapse

Identifiers

PMID40487589
PMCPMC12137205

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.